In vitro activities of moxifloxacin and tigecycline against bacterial isolates associated with intraabdominal infections at a medical center in Taiwan, 2001-2006

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 28, Issue 12, 2009, Pages 1437-1442

  Liu, C Y ^a   Lu, C L ^a   Huang, Y T ^a   Liao, C H ^b   Hsueh, P R ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; IMIPENEM; MOXIFLOXACIN; TIGECYCLINE;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ARTICLE; ESCHERICHIA COLI; HUMAN; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; TAIWAN;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTERIA; BACTERIAL INFECTIONS; BACTERIAL PROTEINS; BETA-LACTAMASES; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; PERITONITIS; QUINOLINES; TAIWAN;

EID: 71349086496     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-009-0801-x     Document Type: Article

References (28)

1. EJ Goldstein DM Citron YA Warren KL Tyrrell CV Merriam H Fernandez 2006 In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections Antimicrob Agents Chemother 50 148 155 10.1128/AAC.50.1.148-155.2006 1:CAS:528:DC%2BD28XivVGluw%3D%3D 16377680 (Pubitemid 43042915)
2. JS Solomkin JE Mazuski EJ Baron RG Sawyer AB Nathens JT DiPiro, et al. 2003 Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections Clin Infect Dis 37 997 1005 10.1086/378702 14523762 (Pubitemid 37323652)
3. PR Hsueh Hawkey 2007 Consensus statement on antimicrobial therapy of intra-abdominal infections in Asia Int J Antimicrob Agents 30 129 133 10.1016/j.ijantimicag.2007.03.002 1:CAS:528:DC%2BD2sXntFart78%3D 17467246 (Pubitemid 46992712)
4. CY Liu YT Huang CH Liao LC Yen HY Lin PR Hsueh 2008 Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems Antimicrob Agents Chemother 52 3161 3168 10.1128/AAC.00355-08 1:CAS:528:DC%2BD1cXhtF2gtrbI 18625771
5. MA Malangoni J Song J Herrington S Choudhri P Pertel 2006 Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections Ann Surg 244 204 211 10.1097/01.sla.0000230024.84190.a8 16858182 (Pubitemid 44305534)
6. ED Hermsen LB Hovde KA Sprandel KA Rodvold JC Rotschafer 2005 Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model Antimicrob Agents Chemother 49 685 689 10.1128/AAC.49.2.685-689.2005 1:CAS:528:DC%2BD2MXht12ntLY%3D 15673752 (Pubitemid 40175681)
7. CE Edmiston CJ Krepel GR Seabrook LR Somberg A Nakeeb RA Cambria, et al. 2004 In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections Antimicrob Agents Chemother 48 1012 1016 10.1128/AAC.48.3.1012-1016. 2004 1:CAS:528:DC%2BD2cXitVGhtb4%3D 14982797 (Pubitemid 38280357)
8. SK Bouchillon DJ Hoban BM Johnson JL Johnson A Hsiung MJ Dowzicky, et al. 2005 In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004) Diagn Microbiol Infect Dis 52 173 179 10.1016/j.diagmicrobio.2005.06.004 1:CAS:528:DC%2BD2MXos1aitrY%3D 16105561 (Pubitemid 41133542)
9. SK Bouchillon JR Iredell T Barkham K Lee MJ Dowzicky 2009 Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST) Int J Antimicrob Agents 33 130 136 10.1016/j.ijantimicag.2008.07.031 1:CAS:528:DC%2BD1MXktlCqtQ%3D%3D 18995992
10. PA Bradford DT Weaver-Sands PJ Petersen 2005 In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections Clin Infect Dis 41 Suppl 5 S315 S332 10.1086/431673 1:CAS:528:DC%2BD2MXhtVWnu7fN 16080070 (Pubitemid 41170379)
11. NC Cheng PR Hsueh YC Liu JM Shyr WK Huang LJ Teng, et al. 2005 In vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in Taiwan Microb Drug Resist 11 330 341 10.1089/mdr.2005.11.330 1:CAS:528:DC%2BD2MXhtlWhtL7I 16359192 (Pubitemid 43099770)
12. MJ Dowzicky CH Park 2008 Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007 Clin Ther 30 2040 2050 10.1016/j.clinthera.2008.11.006 1:CAS:528:DC%2BD1MXhsV2gu7w%3D 19108792
13. TR Fritsche PA Strabala HS Sader MJ Dowzicky RN Jones 2005 Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates Diagn Microbiol Infect Dis 52 209 213 10.1016/j.diagmicrobio.2005.06.010 1:CAS:528:DC%2BD2MXos1ait70%3D 16105566 (Pubitemid 41133547)
14. T Kelesidis DE Karageorgopoulos I Kelesidis ME Falagas 2008 Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies J Antimicrob Chemother 62 895 904 10.1093/jac/dkn311 1:CAS:528:DC%2BD1cXht1eksr7M 18676620
15. CY Liu YT Huang CH Liao PR Hsueh 2008 In vitro activities of tigecycline against clinical isolates of Aeromonas, Vibrio, and Salmonella species in Taiwan Antimicrob Agents Chemother 52 2677 2679 10.1128/AAC.00002-08 1:CAS:528:DC%2BD1cXot1OhtLs%3D 18474585 (Pubitemid 351915708)
16. RR Reinert DE Low F Rossi X Zhang C Wattal MJ Dowzicky 2007 Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline J Antimicrob Chemother 60 1018 1029 10.1093/jac/dkm310 1:CAS:528: DC%2BD2sXht1ShtrnE 17855724 (Pubitemid 47617749)
17. ML Townsend MW Pound RH Drew 2007 Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections Ther Clin Risk Manag 3 1059 1070 1:CAS:528:DC%2BD1cXhtVOksrk%3D 18516315
18. F Baquero PR Hsueh DL Paterson F Rossi GV Bochicchio G Gallagher, et al. 2009 In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2005 results from Study for Monitoring Antimicrobial Resistance Trends (SMART) Surg infect 10 2 99 104 10.1089/sur.2008.0020
19. M Guembe E Cercenado L Alcalá M Marín R Insa E Bouza 2008 Evolution of antimicrobial susceptibility patterns of aerobic and facultative gram-negative bacilli causing intra-abdominal infections: results from the SMART studies 2003-2007 Rev Esp Quimioter 21 166 173 1:STN:280:DC%2BD1cngsFGnuw%3D%3D 18792817
20. JA Passarell AK Meagher K Liolios BB Cirincione SA Van Wart T Babinchak, et al. 2008 Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections Antimicrob Agents Chemother 52 204 210 10.1128/AAC.00813-07 1:CAS:528:DC%2BD1cXkslehtA%3D%3D 17954694
21. GV Bochicchio F Baquero PR Hsueh DL Paterson F Rossi TA Snyder, et al. 2006 In vitro susceptibilities of Escherichia coli isolated from patients with intra-abdominal infections worldwide in 2002-2004: results from SMART (Study for Monitoring Antimicrobial Resistance Trends) Surg Infect 7 537 545 10.1089/sur.2006.7.537 (Pubitemid 46348304)
22. JW Chow V Satishchandran TA Snyder CM Harvey IR Friedland MJ Dinubile 2005 In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART) Surg Infect (Larchmt) 6 439 448 10.1089/sur.2005.6.439 (Pubitemid 43263283)
23. PR Hsueh TA Snyder MJ Dinubile V Satischandran K McCarroll JW Chow, et al. 2006 In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends) Int J Antimicrob Agents 28 238 243 10.1016/j.ijantimicag. 2006.04.010 1:CAS:528:DC%2BD28XotlGqtrY%3D 16904295 (Pubitemid 44223984)
24. Clinical and Laboratory Standards Institute (CLSI) (2008) Performance standards for antimicrobial susceptibility testing; 16th informational supplement. CLSI document M100-S18. CLSI, Wayne, PA
25. Committee ECoASTS 2006 EUCAST technical note on tigecycline Clin Microbiol Infect 12 1147 1149 10.1111/j.1469-0691.2006.01578.x (Pubitemid 44462854)
26. F Rossi F Baquero PR Hsueh DL Paterson GV Bochicchio TA Snyder, et al. 2006 In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends) J Antimicrob Chemother 58 205 210 10.1093/jac/dkl199 1:CAS:528:DC%2BD28Xms1Onsr4%3D 16717055 (Pubitemid 44295010)
27. DL Paterson F Rossi F Baquero PR Hsueh GL Woods V Satishchandran, et al. 2005 In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART) J Antimicrob Chemother 55 965 973 10.1093/jac/dki117 1:CAS:528:DC%2BD2MXmtVarsLY%3D 15849262 (Pubitemid 40883183)
28. HS Sader RN Jones MG Stilwell MJ Dowzicky TR Fritsche 2005 Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents Diagn Microbiol Infect Dis 52 181 186 10.1016/j.diagmicrobio.2005. 05.005 1:CAS:528:DC%2BD2MXos1aitrc%3D 16105562 (Pubitemid 41133543)